全球急性肌张力不全症市场按药物类别、年龄层、分销管道和地区划分

2025 年全球急性肌张力不全症市场规模估计为 1.208 亿美元，预计到 2032 年将达到 1.526 亿美元，2025 年至 2032 年的复合年增长率为 3.4%。

数字。 2025年全球市场占有率急性肌张力不全症市场各地区份额（%）

急性肌张力不全症是一种运动障碍，其特征是导致重复运动和异常姿势的不自主肌肉收缩。这些收缩可能会很痛苦，通常是由突然的肌肉痉挛引起的。急性肌张力不全症可影响身体的任何部位，包括颈部（颈部肌肌张力不全症）、眼睛（眼部肌肌张力不全症）、下颚或舌头或四肢。这种症状可能有多种原因，包括：

• 药物引起的肌张力不全症：这是最常见的原因之一。它可能是某些药物的副作用，特别是抗精神病药物，会影响大脑中的多巴胺路径。
• 特发性肌张力不全症：病因不明。
• 次发性肌张力不全症：由威尔森氏症、亨丁顿舞蹈症、巴金森氏症、脑损伤或中风等潜在疾病所引起。

市场动态

全球急性肌肌张力不全症市场的发展受到引发急性肌肌张力不全症失调的神经系统疾病（如帕金森氏症、脑性麻痹和迟发性）盛行率上升的推动。例如，根据世界卫生组织（WHO）2024年8月9日发布的报告，巴金森氏症（PD）是一种导致运动、心理健康、睡眠、疼痛和其他健康问题的脑部疾病。 2021年，美国有近100万人患有帕金森氏症（PD），预计到2030年这数字将增加至120万人。帕金森氏症是继阿兹海默症之后第二常见的神经退化性疾病。

此外，根据美国生物技术资讯中心2022年3月发布的报告，美国每年每1,000名幼儿中就有2.3至3.6名患有脑性麻痹。痉挛型脑性麻痹是最常见的类型，占所有脑性麻痹的61%至76.9%。

研究的主要特点

• 本报告对全球急性肌张力不全症市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率(CAGR)。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、业绩和策略等参数，介绍了全球急性肌肌张力不全症市场的主要企业概况。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
• 全球急性肌张力不全症市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
• 相关人员将透过全球急性肌肌张力不全症市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 肌张力不全症不断上升
  • 药物相关副作用
  • 了解不断变化的治疗模式
• 监管指南
• 市场趋势
• PEST分析
• 投资与资金筹措
• 合併、收购和合作
• 产品映射
• 识别顶级市场参与企业
• 市场参与企业采取各种业务发展策略
• 国家医疗费用支出

4. 全球急性肌张力不全症市场-冠状病毒（COVID-19）大流行的影响

• COVID-19流行病学
• 供需侧分析
• 经济影响

5. 2020 年至 2032 年全球急性肌张力不全症市场（依药物类别）

• 介绍
• 抗胆碱药物
• 苯二氮平类药物
• 其他（神经毒素等）

6. 全球急性肌张力不全症市场（依年龄层划分），2020 年至 2032 年

• 介绍
• 婴儿
• 成人

7. 2020 年至 2032 年全球急性肌张力不全症市场（依通路划分）

• 介绍
• 医院药房
• 零售药局
• 网路药局

8. 全球急性肌张力不全症市场（按地区），2020 年至 2032 年

• 介绍
• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东
• 非洲

第九章 竞争态势

• 公司简介
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • SSPharmachem
  • Remedy Labs
  • Wan Bury
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

第 10 章 章节

• 参考
• 调查方法
• 关于出版商

Global Acute Dystonia Market is estimated to be valued at USD 120.8 Mn in 2025 and is expected to reach USD 152.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 3.4% from 2025 to 2032.

Figure. Global Acute Dystonia Market Share (%), By Region 2025

Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:

• Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
• Idiopathic Dystonia: Where the cause is unknown
• Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke

Market Dynamics:

The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2024, according to a report published by the World Health Organization (WHO), Parkinson's disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.

Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global acute dystonia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market

Detailed Segmentation:

• Global Acute Dystonia Market, By Drug Class
  • Anticholinergic Agents
  • Benzodiazepines
  • Others (Neurotoxin, etc.)
• Global Acute Dystonia Market, By Age Group
  • Children
  • Adult
• Global Acute Dystonia Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Acute Dystonia Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F.Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Age Group
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of dystonia
  • Side effects associated with drugs
  • Understanding changing treatment patterns
• Key Highlights
• Regulatory Guidelines
• Market Trends
• PEST Analysis
• Investments and Funding
• Mergers, Acquisitions, and Collaborations
• Product Mapping
• Identification of Top Market Players
• Adoption of Various Business Development Strategies by the Market players
• Healthcare Spending by Country

4. Global Acute Dystonia Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Acute Dystonia Market, By Drug Class, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Anticholinergic Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Neurotoxin, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Acute Dystonia Market, By Age Group, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Acute Dystonia Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Acute Dystonia Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profile
  • Fresenius Kabi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
• Analyst Views

10. Section

• References
• Research Methodology
• About us